Success Metrics

Clinical Success Rate
85.4%

Based on 41 completed trials

Completion Rate
85%(41/48)
Active Trials
3(5%)
Results Posted
2%(1 trials)
Terminated
7(11%)

Phase Distribution

Ph phase_2
3
5%
Ph phase_3
5
8%
Ph not_applicable
18
28%
Ph phase_1
2
3%

Phase Distribution

2

Early Stage

3

Mid Stage

5

Late Stage

Phase Distribution28 total trials
Phase 1Safety & dosage
2(7.1%)
Phase 2Efficacy & side effects
3(10.7%)
Phase 3Large-scale testing
5(17.9%)
N/ANon-phased studies
18(64.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.7%

41 of 49 finished

Non-Completion Rate

16.3%

8 ended early

Currently Active

3

trials recruiting

Total Trials

64

all time

Status Distribution
Active(3)
Completed(41)
Terminated(8)
Other(12)

Detailed Status

Completed41
unknown12
Terminated7
Recruiting3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
64
Active
3
Success Rate
85.4%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (7.1%)
Phase 23 (10.7%)
Phase 35 (17.9%)
N/A18 (64.3%)

Trials by Status

withdrawn12%
completed4164%
terminated711%
recruiting35%
unknown1219%

Recent Activity

Clinical Trials (64)

Showing 20 of 64 trialsScroll for more
NCT01721343Not Applicable

Collaborative Targeted Case Management in Improving Functional Status in Patients With Stage III-IV Cancer

Completed
NCT05790538

Predicting the Impact of Treatment Toxicities on Health During Cancer ( PATTERN )

Completed
NCT00736749

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Recruiting
NCT01790152

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Recruiting
NCT00719966

Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer

Completed
NCT00303914

Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer

Completed
NCT01407770

Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer

Completed
NCT01478477Not Applicable

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

Completed
NCT01416688

S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride

Completed
NCT00530049

Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure

Completed
NCT01366183

Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Unknown
NCT00735514

Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer

Completed
NCT01243541Not Applicable

Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel

Terminated
NCT02240381Not Applicable

Predicting Development of Diabetes Mellitus in Patients Undergoing Allogeneic Stem Cell Transplant

Terminated
NCT00874211

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Completed
NCT01372787

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Unknown
NCT00949052

Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer

Terminated
NCT01590147Not Applicable

Supportive Intervention Programs Study

Completed
NCT01483196Not Applicable

Vascular and Cognitive Assessments in Patients With Breast Cancer Undergoing Chemotherapy After Surgery

Completed
NCT00665782

Measuring Stress in Women With Newly Diagnosed Stage I, Stage II, or Stage III Breast Cancer or Ductal Carcinoma In Situ of the Breast

Completed

Drug Details

Intervention Type
PROCEDURE
Total Trials
64